相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Gustavo Luna et al.
JAMA NEUROLOGY (2020)
Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions
Kristen M. Krysko et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis
Kristen M. Krysko et al.
ANNALS OF NEUROLOGY (2020)
Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses A Systematic Review and Meta-analysis
Kristen M. Krysko et al.
JAMA NEUROLOGY (2020)
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Anna He et al.
LANCET NEUROLOGY (2020)
Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort
Annette Langer-Gould et al.
NEUROLOGY (2020)
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study
Luca Prosperini et al.
NEUROTHERAPEUTICS (2020)
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder
Andrea Ines Ciplea et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
An Italian programme for COVID-19 infection in multiple sclerosis
Maria Pia Sormani
LANCET NEUROLOGY (2020)
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
Helmut Butzkueven et al.
BMJ OPEN (2020)
Cladribine vs other drugs in MS Merging randomized trial with real-life data
Alessio Signori et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
Beatriz Canibano et al.
JOURNAL OF DRUG ASSESSMENT (2020)
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation
Jeffrey A. Cohen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches
Andrea Berardi et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists
Joyutpal Das et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
Katharine Harding et al.
JAMA NEUROLOGY (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies
Lori Mayer et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Risk of relapses during pregnancy among multiple sclerosis patients
Raed Alroughani et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
J. William L. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Evolution of clinical trials in multiple sclerosis
Yinan Zhang et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
Jing Chen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Mathias Granqvist et al.
JAMA NEUROLOGY (2018)
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Tanuja Chitnis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US
Kristen M. Krysko et al.
NEUROLOGY (2018)
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatmentnai-naive patients with multiple sclerosis
Luca Prosperini et al.
JOURNAL OF NEUROLOGY (2017)
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
Nathaniel Lizak et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis
Hyunwoo Lee et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans
Rachel E. Ventura et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis
Hyunwoo Lee et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans
Rachel E. Ventura et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Tomas Kalincik et al.
LANCET NEUROLOGY (2017)
Disease-modifying therapies modulate retinal atrophy in multiple sclerosis A retrospective study
Julia Button et al.
NEUROLOGY (2017)
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
Jeffrey M. Gelfand et al.
NEUROTHERAPEUTICS (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Paolo A. Muraro et al.
JAMA NEUROLOGY (2017)
Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies
Ai-Lan Nguyen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Rituximab in paediatric onset multiple sclerosis: a case series
Jonatan Salzer et al.
JOURNAL OF NEUROLOGY (2016)
Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis
Vilija G. Jokubaitis et al.
ANNALS OF NEUROLOGY (2016)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Brain health: time matters in multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
Raed Alroughani et al.
PLOS ONE (2016)
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS
Tim Spelman et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Tomas Kalincik et al.
ANNALS OF NEUROLOGY (2015)
Natalizumab in the pediatric MS population: results of the Italian registry
Angelo Ghezzi et al.
BMC NEUROLOGY (2015)
Defining high, medium and low impact prognostic factors for developing multiple sclerosis
Mar Tintore et al.
BRAIN (2015)
Multiple sclerosis and pregnancy in the 'treatment era'
Sandra Vukusic et al.
NATURE REVIEWS NEUROLOGY (2015)
JC virus antibody status in a pediatric multiple sclerosis cohort: Prevalence, conversion rate and influence on disease severity
Peter Huppke et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Comparative efficacy of switching to natalizumab in active multiple sclerosis
Timothy Spelman et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Monoclonal antibodies in treatment of multiple sclerosis
P. S. Rommer et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Predictors and dynamics of postpartum relapses in women with multiple sclerosis
Stella E. Hughes et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study
E. Leray et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Predictive value of 1 month retinal nerve fiber layer thinning for deficits at 6 months after acute optic neuritis
Mark J. Kupersmith et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
David B. Clifford et al.
ARCHIVES OF NEUROLOGY (2011)
Management of Pediatric Central Nervous System Demyelinating Disorders: Consensus of United States Neurologists
Amy T. Waldman et al.
JOURNAL OF CHILD NEUROLOGY (2011)
The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
Antonio Scalfari et al.
BRAIN (2010)
Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later
Thomas F. Scott et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2010)
Early cognitive impairment in multiple sclerosis predicts disability outcome several years later
Mathilde Deloire et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis
Mark P. Gorman et al.
ARCHIVES OF NEUROLOGY (2009)
Demyelinating events in early multiple sclerosis have inherent severity and recovery
E. M. Mowry et al.
NEUROLOGY (2009)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis
BAC Cree et al.
NEUROLOGY (2004)
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse
S Vukusic et al.
BRAIN (2004)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
PA Brex et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Short-term prognosis in early relapsing-remitting multiple sclerosis
TF Scott et al.
NEUROLOGY (2000)
分享论文
